Physician profile
Audrey Ormberg
NPI 1891781506
$3,736.30
in general payments reported to CMS, 2019-2025
21 companies · $946 in 2025
The $946 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $143 · 2021: $438 · 2022: $672 · 2023: $254 · 2024: $1,149 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,615.09 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $599.47 | 2020-2024 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $327.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $294.31 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.80 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.29 | 2024 | Jardiance |
| Medtronic, INC. | $99.53 | 2025 | Closurefast |
| Lilly USA, LLC | $85.70 | 2022-2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $79.36 | 2019 | |
| Pfizer INC. | $75.52 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $74.20 | 2019-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $50.87 | 2019-2025 | Trelegy Ellipta, Shingrix, Penmenvy |
| Exact Sciences Corporation | $27.96 | 2025 | The Cologuard Plus Collection Kit |
| Acadia Pharmaceuticals INC | $21.24 | 2020 | |
| Dexcom, INC. | $19.94 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.06 | 2022 | |
| Sumitomo Pharma America, INC. | $17.97 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $17.02 | 2024 | Voquezna |
| Evofem Biosciences, INC. | $15.16 | 2021 | |
| Cranial Technologies, INC | $12.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Ormberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.